Incyte expands Opzelura partnership to Australia

Incyte ($INCY) expanded its partnership with Specialised Therapeutics to include Opzelura in Australia. The arrangement assigns local regulatory submissions, medical affairs, marketing and distribution responsibilities to the partner, while Incyte retains responsibility for development and manufacturing. It creates a route for pursuing Australian access to the treatment.

The expansion does not itself establish Australian marketing approval, reimbursement or a commercial launch. Approvals already obtained in other markets should not be read as automatic authorization in Australia. The companies did not disclose the agreement’s financial terms, local sales expectations or a guaranteed launch timetable. The near-term significance is the establishment of regulatory and commercial responsibilities in an additional market, with patient access still dependent on the applicable processes.

Sources:

• Specialised Therapeutics — expanded Incyte partnership, corporate release reprinted by StockTitan